Janux Therapeutics amasses $56m Series A
Janux Therapeutics, a developer of immunotherapies, has secured $56 million in Series A financing.
Janux Therapeutics, a developer of immunotherapies, has secured $56 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination